heptanol has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Emmett, T; Kargacin, G; Nygren, A; Schmidt, R; Shimoni, Y | 1 |
| Alexandru, N; Constantinescu, E; Georgescu, A; Popov, D | 1 |
2 other study(ies) available for heptanol and Alloxan Diabetes
| Article | Year |
|---|---|
Sex-dependent impairment of cardiac action potential conduction in type 1 diabetic rats.
Topics: Action Potentials; Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Connexin 43; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; Gap Junctions; Heart Conduction System; Heptanol; Male; Ovariectomy; Quinapril; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Sex Factors; Tetrahydroisoquinolines; Time Factors | 2009 |
Effect of gap junction uncoupler heptanol on resistance arteries reactivity in experimental models of diabetes, hyperlipemia and hyperlipemia-diabetes.
Topics: Acetylcholine; Animals; Arginine; Cholesterol, Dietary; Cricetinae; Diabetes Mellitus, Experimental; Gap Junctions; Heptanol; Hyperlipidemias; Male; Mesenteric Arteries; Mesocricetus; Nitroprusside; Norepinephrine; Potassium Chloride; Streptozocin; Vascular Resistance; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2006 |